Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Colombo

Showing results (341-350 of 372) with videos related to

Pageof 38
Sort By:
Gastroenterology|February 12, 2009
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyThierry Poynard, Massimo Colombo, Jordi Bruix, et al.
Hepatology (Baltimore, Md.)|October 31, 2015
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infectionMaria Antonella Burza, Benedetta Maria Motta, Rosellina Margherita Mancina, et al.
Journal of Hepatology|November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ programThierry Poynard, Mona Munteanu, Massimo Colombo, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Oncotarget|April 11, 2018
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinomaFarzaneh Moshiri, Alessandro Salvi, Laura Gramantieri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.
Pageof 38

Showing results (341-350 of 372) with videos related to

Sort By:
Pageof 38
Gastroenterology|February 12, 2009
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyThierry Poynard, Massimo Colombo, Jordi Bruix, et al.
Hepatology (Baltimore, Md.)|October 31, 2015
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infectionMaria Antonella Burza, Benedetta Maria Motta, Rosellina Margherita Mancina, et al.
Journal of Hepatology|November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ programThierry Poynard, Mona Munteanu, Massimo Colombo, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Oncotarget|April 11, 2018
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinomaFarzaneh Moshiri, Alessandro Salvi, Laura Gramantieri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.
Pageof 38